Investigational Combination of First-in-Class Bispecifics TALVEY and TECVAYLI Shows Deep and Durable Responses in Heavily Pretreated Multiple Myeloma Patients With Extramedullary Disease
June 17, 2025
June 17, 2025
RARITAN, New Jersey, June 17 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:
* * *
Investigational combination of first-in-class bispecifics TALVEY and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent ov . . .
* * *
Investigational combination of first-in-class bispecifics TALVEY and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent ov . . .